



ELSEVIER

Contents lists available at ScienceDirect

Fitoterapia

journal homepage: www.elsevier.com/locate/fitote

Q1 Nitric oxide inhibitory flavonoids from traditional Chinese medicine formula Baoyuan Decoction

Q2 Xiaoli Ma, Qian Yu, Xiaoyu Guo, Kewu Zeng, Mingbo Zhao, Pengfei Tu, Yong Jiang*

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China

ARTICLE INFO

Article history:

Received 4 March 2015

Accepted in revised form 9 April 2015

Accepted 12 April 2015

Available online xxxx

Keywords:

Flavonoids

Baoyuan Decoction

Traditional Chinese medicine formula

NO inhibition

UPLC-Q-trap-MS

ABSTRACT

Three new flavonoid glycosides, (3R)-(+)-isomucronulatol-2'-O-β-D-glucopyranoside (**1**), (3R)-(-)-isomucronulatol-7-O-β-D-apiofuranosyl(1 → 2)-β-D-glucopyranoside (**2**), and (2S)-(-)-7,8-dihydroxyflavanone-4'-O-β-D-apiofuranosyl(1 → 2)-β-D-glucopyranoside (**3**), along with eight flavanones (**4**, **8**, **10**, **12**, **15**, **16**, **21**, and **24**), four isoflavones (**5**, **11**, **13**, and **23**), four chalcones (**6**, **14**, **17**, and **18**), two isoflavans (**19–20**), one flavone (**7**), one flavonol (**9**), and one dihydrochalcone (**22**) were isolated from Baoyuan Decoction (BYD), a traditional Chinese medicine formula. The structures of the new compounds were established by detailed analysis of NMR and HRESIMS spectroscopic data, and their absolute configurations were determined by electronic circular dichroism (ECD) data. The inhibitory effects of the isolates were evaluated on nitric oxide production in lipopolysaccharide activated RAW 264.7 macrophage cells. Compounds **6**, **9**, and **10** showed the significant inhibitory activities, with IC₅₀ values of 1.4, 13.8, and 9.3 μM, respectively, comparable to or even better than the positive control, quercetin (IC₅₀, 16.5 μM). The assignment of these isolated flavonoids was achieved using UPLC-Q-trap-MS, and the results suggested that they were originated from *Astragalus membranaceus* and *Glycyrrhiza uralensis*.

© 2015 Elsevier B.V. All rights reserved.

Q3 1. Introduction

In recent years, traditional Chinese medicines (TCMs) have attracted more and more attention in many countries due to their high efficacy and low toxicity [1]. TCM prescription is a formula consisting of several single herbs at an intrinsic mass ratio, containing hundreds or thousands of chemical components [2]. The pharmacological effects of TCM formula are principally based on the synergic effects of multi-ingredients of each herb contained and their combined actions on different targets [3,4].

Baoyuan Decoction (BYD), a well-known traditional TCM formula, being composed of *Astragalus membranaceus* (Fisch.) Bunge. (Leguminosae), *Panax ginseng* C. A. Mey (Araliaceae), *Glycyrrhiza uralensis* Fisch. (Leguminosae), and *Cinnamomum cassia* Presl. (Lauraceae), has been used for the treatment of

aplastic anemia, chronic renal failure, coronary heart disease, etc. [5–7]. In our preliminary analytical work, the flavonoids and saponins were found to be the main constituents contained in BYD (data not shown). Flavonoids, as one of the important natural products, exhibited diverse biological activities for the treatment of cardiovascular diseases, such as improving blood vessels elasticity, affecting coronary artery expansion, reducing blood pressure, antioxidation, and antiplatelet aggregation [8,9]. In order to make clear the flavonoids constitution in BYD and search for the active flavonoids, the water extract of BYD was studied to afford three new flavonoid glycosides (**1–3**), along with eight flavanones (**4**, **8**, **10**, **12**, **15**, **16**, **21**, and **24**), four isoflavones (**5**, **11**, **13**, and **23**), four chalcones (**6**, **14**, **17**, and **18**), two isoflavans (**19–20**), one flavone (**7**), one flavonol (**9**), and one dihydrochalcone (**22**). Their structures (Fig. 1) were established by detailed analysis of NMR and HRESIMS spectroscopic data, and the absolute configurations were determined by electronic circular dichroism (ECD) data. The inhibitory effects of the isolates were evaluated on nitric oxide

* Corresponding author. Tel./fax: +86 10 82802719.
E-mail address: yongjiang@bjmu.edu.cn (Y. Jiang).




Fig. 1. Chemical structures of isolated compounds 1–24 from BYD.

68 (NO) production in lipopolysaccharide (LPS) activated RAW
 69 264.7 macrophage cells. Herein, the isolation and structure
 70 elucidation of the new compounds, and their sources and NO
 71 production inhibitory activities are reported.

72 2. Experimental

73 2.1. General experimental procedures

74 Melting points were determined on an X-4 micro melting
 75 point apparatus (Beijing Fukai Tech Instruments Co., Beijing,
 76 China) and were incorrect. The FT-IR spectra were measured
 77 using a Nicolet NEXUS-470 infrared spectrometer. NMR spectra
 78 were obtained on a Varian 500 spectrometer or a Bruker 400
 79 spectrometer, with deuterated solvent as reference. HRESIMS
 80 spectra were recorded on a Waters Xevo G2 Q-TOF mass
 81 spectrometer equipped with electrospray ionization source in
 82 negative mode. ECD spectra were measured on a JASCO J-810
 83 spectropolarimeter. Analytical HPLC was performed on an

Agilent 1100 HPLC system, equipped with a photodiode array 84
 detector and an Agilent ZORBAX SB-Aq column (250 × 4.6 mm, 85
 5 μm). Semi-preparative HPLC was carried out on an Agilent 86
 1200 instrument, using an Agilent ZORBAX SB-Aq column 87
 (250 × 10 mm, 5 μm), detected with a variable-wavelength 88
 (190 to 600 nm) detector (VWD). Column chromatography 89
 (CC) was performed with macroporous resin AB-8 (Cangzhou 90
 Bon Adsorber Technology Co.), silica gel (100–200 mesh or 91
 200–300 mesh, Qingdao Haiyang Chemical Works), ODS 92
 (Merck), and Sephadex LH-20 (Pharmacia Co.). Analytical 93
 grade solvents were purchased from Beijing Chemical Factory. 94
 D-Apiose solution and D-glucose were obtained from Sigma- 95
 Aldrich (St. Louis, MO, USA). 96

97 2.2. Plant materials

The dried roots of *Panax ginseng*, the decoction pieces of 98
Glycyrrhiza uralensis and *Astragalus membranaceus*, and the 99
 barks of *Cinnamomum cassia* were purchased from Anguo 100

101 traditional Chinese medicine market (Hebei Province, China).
 102 The plant materials were authenticated by Prof. P.F. Tu. The
 103 voucher specimens (PG-AG-20130312; GU-AG-20130312;
 104 AM-AG-20130312; CC-AG-20130312) were deposited in the
 105 herbarium of Modern Research Center for Traditional Chinese
 106 Medicine, Peking University, Beijing, China.

107 2.3. Sample preparation

108 *For extraction and isolation:* the dried roots of *A. membranaceus*
 109 (30 kg), *P. ginseng* (10 kg), *G. uralensis* (10 kg), and the bark of
 110 *C. cassia* (5 kg) were powdered and mixed together, and
 111 extracted with the deionized water (550 L × 3), each for two
 112 hours. The extract was filtered and concentrated in vacuo. The
 113 resulting residue was dissolved in H₂O and subjected to
 114 macroporous resin AB-8 column (30 L) eluting with water and
 115 aqueous ethanol solution (15%, 30%, 50%, and 95% EtOH) to give
 116 five fractions, respectively.

117 The 50% aqueous ethanol eluate (623.3 g) was subjected to
 118 silica gel CC (6 kg) eluting with the gradient of CH₂Cl₂–MeOH–
 119 H₂O (95:5:0.5, 90:10:1, 85:15:1.5, 80:20:2, and 70:30:3) to
 120 give 10 subfractions, Frs. A–J. Compound **5** (22 mg) was
 121 furnished from Fr. B by recrystallization from CH₂Cl₂–MeOH
 122 mixture. Fr. C (38 g) was subjected to Sephadex LH-20 CC
 123 eluting with MeOH to give three fractions, Frs. C₁ (4 g), C₂
 124 (19 g), and C₃ (8 g). Fr. C₂ was applied to silica gel CC (600 g)
 125 eluting with CH₂Cl₂–MeOH–H₂O (90:10:1, 85:15:1.5, 80:20:2,
 126 70:30:3) to afford **4** (8 g) and **6** (56 mg). Fr. D (3 g) was
 127 subjected to Sephadex LH-20 CC eluting with MeOH to give 10
 128 fractions, Frs. D₁–D₁₀. Fr. D₅ furnished **7** (8 mg) by recrystal-
 129 lization from CH₂Cl₂–MeOH mixture. Fr. D₇ (20 mg) was
 130 further chromatographed on ODS using 10–50% aqueous
 131 MeOH as eluents to afford **19** (5 mg). Fr. E (1.9 g) was
 132 subjected to Sephadex LH-20 CC eluting with MeOH to give six
 133 fractions, Frs. E₁–E₆. Compound **1** (15 mg) was precipitated
 134 from Fr. E₃. The remaining residue of Fr. E₃ was separated on
 135 ODS CC eluting with 10–80% aqueous MeOH to yield **8** (6 mg), **9**
 136 (4 mg), and **10** (5 mg). Fr. F (1.5 g) was applied to Sephadex LH-
 137 20 CC using MeOH as eluent to yield **11** (25 mg). Fr. G (2.5 g)
 138 was further chromatographed on silica gel CC (100 g) eluting
 139 with CH₂Cl₂–MeOH–H₂O (85:15:10) to give five fractions, Frs.
 140 G₁ (170 mg), G₂ (890 mg), G₃ (554 mg), G₄ (155 mg), and G₅
 141 (20 mg). Fr. G₂ was further chromatographed on ODS CC eluting
 142 with 10–70% aqueous MeOH to afford **12** (500 mg). Frs. G₃, G₄,
 143 and G₅ were combined and applied to ODS MPLC CC, eluting
 144 with 5–70% aqueous MeOH to give **2** (4 mg), **13** (14 mg), **14**
 145 (8 mg), **15** (14 mg), and **16** (10 mg). Fr. I (3.4 g) was first
 146 applied to Sephadex LH-20 CC using MeOH as eluent to yield 17
 147 fractions, Frs. I₁–I₁₇. Compounds **17** (750 mg) and **18** (6 mg)
 148 were yielded from Fr. I₇ by ODS MPLC employing MeOH–H₂O
 149 mixtures (3:7). Compound **20** (6 mg) was furnished from Fr. I₉
 150 by semipreparative HPLC using ACN/H₂O (17:83) as mobile
 151 phase.

152 The 30% aqueous ethanol eluate (513.3 g) was subjected to
 153 silica gel CC (5 kg) eluting with the mixture of CH₂Cl₂–MeOH–
 154 H₂O (95:5:0.5, 90:10:1, 85:15:1.5, 80:20:2, and 70:30:3) to
 155 give 11 fractions, Frs. A–K. Fr. H was first applied to Sephadex
 156 LH-20 CC using MeOH as eluent to yield six fractions, Frs. H₁–
 157 H₆. Fr. H₃ (980 mg) was further chromatographed on ODS
 158 MPLC (10–50% aqueous MeOH) to afford **21** (30 mg) and **22**
 159 (19 mg). Fr. H₅ (1.49 g) was applied to silica gel CC (60 g)

160 eluting with CH₂Cl₂–MeOH–H₂O (90:10:1, 85:15:1.5, 70:30:3) 160
 161 to afford **24** (15 mg). Fr. I was first applied to Sephadex LH-20 161
 162 CC using MeOH as eluent to yield seven fractions, Frs. I₁–I₇. Fr. I₅ 162
 163 (47 mg) was further chromatographed on ODS MPLC (10–50% 163
 164 aqueous MeOH) to afford **23** (14 mg). Fr. K (5.0 g) was 164
 165 subjected to silica gel CC eluting with the mixture of CH₂Cl₂– 165
 166 MeOH–H₂O (95:5:0.5, 90:10:1, 85:15:1.5, 80:20:2, and 166
 167 70:30:3) to yield 10 fractions, Frs. K₁–K₁₀. Fr. K₃ (56 mg) was 167
 168 further chromatographed on ODS MPLC (5–50% aqueous 168
 169 MeOH) to afford crude **3** (8 mg). Pure compound **3** (3 mg) 169
 170 was further purified by semipreparative HPLC using ACN/H₂O 170
 171 (11:89) as mobile phase. 171

2.3.1. (3R)-(+)–isomucronulatol-2'-O-β-D-glucopyranoside (**1**) 172
 Colorless needles; mp 132–133 °C; [α]_D²³ + 44 (c 0.25, 173
 MeOH); UV (MeOH) λ_{max}: 204, 280 nm; CD (MeOH) λ_{max} (Δε): 174
 231 (–13.09), 280 (+4.39) nm; IR (KBr) ν_{max}: 3396, 2928, 175
 1766, 1598, 1502, 1460, 1244, 1062, 845, 631 cm^{–1}; HRESI (–)– 176
 MS m/z: 509.1645 [M + HCOO][–] (calcd for C₂₄H₂₉O₁₂ 177
 509.1659); ¹H and ¹³C NMR data, see Table 1. 178

2.3.2. (3R)-(–)–isomucronulatol-7-O-β-D-apiofuranosyl(1→2)- 179
 2)-β-D-glucopyranoside (**2**) 180
 White amorphous powder; [α]_D²³ –60 (c 0.23, MeOH); UV 181
 (MeOH) λ_{max}: 204, 277 nm; CD (MeOH) λ_{max} (Δε): 232 182
 (–14.01), 279 (+5.02) nm; IR (KBr) ν_{max}: 3396, 2925, 1767, 183
 1504, 1463, 1375, 1244, 1049, 828, 631 cm^{–1}; HRESI (–)–MS 184
 m/z: 595.2031 [M–H][–] (calcd for C₂₈H₃₅O₁₄ 595.2027); ¹H 185
 and ¹³C NMR data, see Table 1. 186

2.3.3. (2S)-(–)–7,8-dihydroxylflavanone-4'-O-β-D-apiofuranosyl 187
 (1→2)-β-D-glucopyranoside (**3**) 188
 Yellowish amorphous powder; [α]_D²³ –22 (c 0.25, MeOH); 189
 UV (MeOH) λ_{max}: 218, 289 nm; CD (MeOH) λ_{max} (Δε): 300 190
 (–2.39) nm; IR (KBr) ν_{max}: 3402, 2942, 2245, 1647, 1600, 191
 1513, 1361, 1057, 826, 629 cm^{–1}; HRESI (–)–MS m/z: 192
 565.1558 [M–H][–] (calcd for C₂₆H₂₉O₁₄ 565.1557); ¹H and ¹³C 193
 NMR data, see Table 1. 194

For LC-MS analysis: the decoction pieces of *A. membranaceus* 195
 (100 g) were crushed into fine powder and extracted twice 196
 with 1 L of distilled water. The extract was concentrated and 197
 the supernatant was freeze-dried. An aliquot (500 mg) of the 198
 freeze-dried powder was dissolved into 10.0 mL of water by 199
 vortexing mix for 1 min. After centrifugation at 9600 rpm 200
 for 10 min, the supernatant (5 mL) was subjected to a 201
 macroporous resin AB-8 column (60 mL) eluting subsequently 202
 with water, 15%, 50%, and 95% aqueous EtOH to give four 203
 eluents (AM0, AM15, AM50, and AM95), respectively. AM50 204
 was concentrated to dryness under reduced pressure, and 205
 dissolved in MeOH (2 mL), and then filtered through a 0.22 μm 206
 membrane before LC/MS analysis. The sample preparation 207
 method was same for the pieces of *G. uralensis*, the crude drugs 208
 of *P. ginseng* and *C. cassia*, and the BYD water extract. 209

210 2.4. Acid hydrolysis 210

Compounds **1** (2.5 mg), **2** (1.4 mg), and **3** (2.4 mg) were 211
 212 respectively hydrolyzed with 2 M aqueous CF₃COOH (5 mL) by 212
 213 thermostat oil bath at 100 °C for 3 h. After the solvent was 213
 214 removed in vacuo with MeOH, and the residue was partitioned 214
 215 between CH₂Cl₂ and H₂O to give the aglycones of **1–3**, which 215

t1.1 **Table 1**
t1.2 ^1H and ^{13}C NMR data of compounds **1–3** (in DMSO- d_6 , δ in ppm and J in Hz).

t1.3	Position	1		2		3	
		δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}
t1.4	2	4.29 dd (3.2, 10.0) 3.81 t (10.0)	69.6	4.26 d (10.3) 4.00 t (10.3)	71.0	5.51 dd (12.4, 2.6)	43.8
t1.5	3	3.60 m	30.3	3.45 m	33.5	3.14 dd (12.4, 16.8) 2.70 dd (16.8, 2.6)	79.3
t1.6	4	2.80 dd (15.6, 11.6) 2.66 dd (15.6, 4.0)	30.9	2.99 dd (15.9, 10.5) 2.85 dd (15.9, 4.6)	31.3		191.0
t1.8	5	6.84 d (8.2)	130.0	6.98 d (8.4)	131.2	7.18 d (8.6)	117.9
t1.9	6	6.27 dd (8.2, 2.2)	107.8	6.59 dd (8.4, 2.5)	110.0	6.52 d (8.6)	110.3
t1.10	7		156.4		158.3		153.0
t1.11	8	6.18 d (2.2)	102.6	6.51 d (2.5)	105.4		133.0
t1.12	9		154.9		156.4		151.6
t1.13	10		112.9		117.7		114.8
t1.14	1'		128.7		122.2		133.3
t1.15	2'		147.6		149.6	7.49 d (8.6)	128.6
t1.16	3'		141.2		137.6	7.05 d (8.6)	116.4
t1.17	4'		152.0		153.2		157.7
t1.18	5'	6.79 d (8.7)	108.6	6.47 d (8.7)	104.4	7.05 d (8.6)	116.4
t1.19	6'	6.90 d (8.7)	121.9	6.78 d (8.7)	122.8	7.49 d (8.6)	128.6
t1.20	3'-OCH ₃	3.73 s	60.5	3.79 s	61.1		
t1.21	4'-OCH ₃	3.77 s	55.8	3.81 s	56.3		
t1.22	1''	4.86 d (6.1)	103.4	4.92 d (7.4)	101.0	4.96 d (7.4)	99.1
t1.23	2''		77.5		78.7		76.5
t1.24	3''		74.0		78.0		77.4
t1.25	4''		70.2		71.4		70.5
t1.26	5''		76.4		78.6		77.5
t1.27	6''	3.69 dd (10.9, 3.9) 3.38 dd (6.0, 10.9)	61.3	3.88 dd (2.0, 12.2) 3.69 dd (5.5, 12.2)	62.5	3.69 dd (2.0, 11.5) 3.45 dd (5.0, 11.5)	61.1
t1.28	1'''			5.46 d (1.4)	110.8	5.36 s	108.7
t1.29	2'''				78.1	3.74 s	76.2
t1.30	3'''				80.8		79.8
t1.31	4'''			4.05 d (9.6) 3.78 d (9.6)	75.5	3.95 d (9.2) 3.65 d (9.2)	74.5
t1.32	5'''			3.55 d (3.7)	66.1	3.32 s	64.8

216 were used for the ECD determination, along with the sugar
217 fractions. The sugar fractions of **1–3** were respectively passed
218 through a Sep-Pak C₁₈ cartridge (Waters, Milford, MA, USA;
219 with 40% MeOH), and then analyzed by HPLC (MeCN–H₂O
220 85:15; flow rate, 1.0 mL/min; CHIRALYSER-MP optical rotation
221 detector). D-glucose (t_{R} 19.7 min, positive optical rotation) was
222 detected from **1**, while D-apiose (t_{R} 7.70 min, positive optical
223 rotation) and D-glucose (t_{R} 19.7 min, positive optical rotation)
224 were detected from **2** and **3**.

225 2.5. Cell culture and NO measurement

226 The macrophage RAW 264.7 cells were obtained from
227 Peking Union Medical College Cell Bank (Beijing, China),
228 cultured in DMEM containing 10% heat-inactivated fetal calf
229 serum, 100 U/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin, and
230 grown at 37 °C with 5% CO₂ in fully humidified air. Cells were
231 plated at a density of 2×10^5 cells/well in 96-well culture
232 plates and stimulated with LPS (1 $\mu\text{g}/\text{mL}$) in the presence or
233 absence of the test compound for 24 h. All compounds were
234 dissolved in DMSO and further diluted with sterile PBS. Nitrite
235 (NO₂⁻) accumulation in the medium was used as an indicator of
236 NO production, which was measured by adding the Griess
237 reagent (1% sulfanilamide and 0.1% naphthylendiamine in 5%
238 phosphoric acid). NaNO₂ was used to generate a standard
239 curve, and nitrite production was determined by measuring
240 optical density at 550 nm. All experiments were performed in

triplicate. NO production by LPS stimulation was designated as 241
100% for each experiment. Quercetin (Sigma, 98.0% HPLC) was 242
employed as a positive control. Cell viability was evaluated by 243
MTT assay. 244

245 2.6. Liquid chromatography and mass spectrometry

246 UPLC analysis was performed with a Waters (Milford, MA) 246
ACQUITY UPLC system equipped with a quaternary solvent 247
manager, sample manager, column-heating compartment, and 248
photodiode array detector. This system was controlled by 249
Waters Empower software. An ACQUITY UPLCTM Cortecs 250
column, 100 \times 2.1 mm, 1.6 μm (Waters) was employed for 251
chromatographic separation. The mobile phase was 0.05% 252
formic acid in water as eluent A and 0.05% formic acid 253
in acetonitrile as eluent B. The elution program was as 254
follows: 0.0–8.0 min, 2%–15% B; 8.0–17.0 min, 15%–25% 255
B; 17.0–22.0 min, 25%–40% B; 22.0–24.0 min, 40%–60% B; 256
24.0–25.0 min, 60%–100% B; 25.0–26.0 min, 100%–100% B; 257
26.0–26.01 min, 100%–2% B; 26.01–31.0 min, 2% B. The flow 258
rate was 0.4 mL/min. 259

260 Mass spectrometry analysis was performed on an ABSciex 260
API 4500 triple quadrupole-linear ion trap mass spectrometer 261
(Q-trap), equipped with an ESI-Turbo Ion-Spray interface, 262
operating in negative ion mode and controlled by Analyst 263
1.6.1 software (AB Sciex). The ESI source operation parameters 264
were as follows: source temperature 550 °C; ion spray voltage 265

266 (IS) 4500 V; ion source gas I (GSI), gas II (GSII), and curtain gas
 267 (CUR) were set at 55, 55, and 35.0 psi, respectively; the collision
 268 gas (CAD) was high.

269 3. Results and discussion

270 Compound **1** was obtained as colorless needles. Its molecular
 271 formula was determined as C₂₃H₂₈O₁₀ from the ¹³C NMR
 272 data and HRESIMS ion at *m/z*: 509.1645 [M + HCOO]⁻ (calcd
 273 for C₂₄H₂₉O₁₂ 509.1659). The IR spectrum of **1** displayed the
 274 absorption bands at 3396 cm⁻¹ (hydroxy group), 2928 cm⁻¹
 275 (methyl group), and 1598, 1502, and 1460 cm⁻¹ (aromatic
 276 group). The ¹H NMR data of **1** showed the presence of a group

of ABX coupled phenyl signals at δ_H 6.84 (1H, d, *J* = 8.2 Hz, 277
 H-5), 6.27 (1H, dd, *J* = 8.2, 2.2 Hz, H-6), and 6.18 (1H, d, *J* = 278
 2.2 Hz, H-8), two *ortho*-coupled aromatic protons at δ_H 6.90 279
 (1H, d, *J* = 8.7 Hz, H-6') and 6.79 (1H, d, *J* = 8.7 Hz, H-5'), two 280
 methoxy groups at δ_H 3.77 (3H, s) and 3.73 (3H, s), and an 281
 anomeric proton at δ_H 4.86 (1H, d, *J* = 6.1 Hz, H-1"). The five 282
 other characteristic aliphatic signals at δ_H 4.29 (1H, dd, *J* = 3.2, 283
 10.0 Hz, H-2a), 3.81 (1H, t, *J* = 10.0 Hz, H-2b), 3.60 (1H, m, 284
 H-3), 2.80 (1H, dd, *J* = 11.6, 15.6 Hz, H-4a), and 2.66 (1H, dd, 285
J = 4.0, 15.6 Hz, H-4b) suggested that **1** is an isoflavan 286
 glycoside. The ¹³C NMR data of **1** showed 23 carbon signals 287
 (Table 1), including 12 aromatic carbons, 3 aliphatic carbons, 2 288
 methoxy carbons, and a group of glucosyl carbons. On acid 289




Fig. 2. UPLC-Q-trap-MS base peak ion chromatograms (BPC) of BYD extract (A), *A. membranaceus* extract (B), and *G. uralensis* extract (C), in negative ion mode.

hydrolysis, **1** yielded D-glucose after HPLC separation and optical rotation measurement. The coupling constant of the anomeric proton ($J = 6.1$ Hz) confirmed the β -configuration of the glucosyl. The HMBC correlations of the anomeric proton of glucosyl H-1''/C-2', H-3/C-1', C-2', C-6', OCH₃-2'/C-2', and OCH₃-3'/C-3' suggested that the linkage positions of the glucosyl and the two methoxy groups are at C-2', 3', and 4', respectively. The ECD data of the aglycone (Supplementary data) produced by acid hydrolysis exhibited a negative CE in 231 nm (¹L_a) and a positive CE in 280 nm (¹L_b), indicating the 3R configuration for **1** [10]. Thus, compound **1** was determined as (3R)-(+)-isomucronulatol-2'-O- β -D-glucopyranoside.

Compound **2** was obtained as a white amorphous powder. Its molecular formula was determined as C₂₈H₃₆O₁₄ from the ¹³C NMR and HRESIMS data (m/z : 595.2031 [M-H]⁻, calcd for C₂₈H₃₆O₁₄ 595.2027). The IR spectrum of **2** displayed absorption bands at 3396 cm⁻¹ (hydroxy group), 2925 cm⁻¹ (methyl group), and 1616, 1505, and 1463 cm⁻¹ (aromatic group). The NMR data of **2** (Table 1) were similar to those of **1** except for a group of additional apiosyl signals [δ_{H} 5.46 (1H, d, $J = 1.5$ Hz, H-1'), δ_{C} 110.8]. Acid hydrolysis afforded glucose and apiose, whose configurations were determined to be D by the optical rotation measurement after HPLC separation. The J value (7.4 Hz) of the anomeric proton of glucosyl suggested a β -D configuration, and the comparison of ¹³C NMR spectroscopic data with literature values supported the β -D apiosyl [12]. The glucosyl moiety was deduced to be linked at C-7 of the aglycone from the HMBC correlation of H-1'' to C-7, and the apiosyl moiety was determined to be connected at C-2' of glucosyl according to the HMBC correlation of H-1''' to C-2''. The absolute configuration of C-3 was determined as 3R by the ECD data [10,13]. Thus, compound **2** was defined as (3R)-(-)-isomucronulatol-7-O- β -D-apiofuranosyl(1 \rightarrow 2)- β -D-glucopyranoside.

Compound **3** was obtained as a yellowish amorphous powder. Its molecular formula was determined as C₂₆H₃₀O₁₄ from the ¹³C NMR and HRESIMS data (m/z : 565.1558 [M-H]⁻, calcd for C₂₆H₃₀O₁₄ 565.1557). The IR spectrum of **3** displayed the absorption bands at 3402 cm⁻¹ (hydroxyl group), 1647 cm⁻¹ (conjugated carbonyl group), and 1600, 1513, and 1462 cm⁻¹ (aromatic group). The ¹H NMR data of **3** showed the presence of three characteristic aliphatic signals of flavanone at δ_{H} 3.14 (1H, dd, $J = 16.8, 12.4$ Hz, H-3a), 2.70 (1H, dd, $J = 16.8, 2.6$ Hz, H-3b), and 5.51 (1H, dd, $J = 12.4, 2.6$ Hz, H-3), a group of AA'BB' coupled aromatic signals at δ_{H} 7.49 (2H, d, $J = 8.6$ Hz, H-2', 6'), 7.05 (2H, d, $J = 8.6$ Hz, H-3', 5'), two AB *ortho*-coupled aromatic protons at δ_{H} 7.18 (1H, d, $J = 8.6$ Hz, H-6'), 6.52 (1H, d, $J = 8.6$ Hz, H-5'), and two anomeric proton signals at δ_{H} 5.36 (1H, s, H-1'''), 4.96 (1H, d, $J = 7.4$ Hz, H-1''). The ¹³C NMR data (Table 1) showed 26 carbon signals, which also provided support that **3** is a flavanone diglycoside. The HMBC correlations of H-5/C-4, C-7, and H-6/C-5, C-7, C-8, C-10 suggested that A ring is 7,8-dihydroxylated. On acid hydrolysis, **3** yielded D-glucose and D-apiose, whose configurations were determined in the same way as in **2** (Supplementary data). The anomeric proton of glucosyl showed correlation with C-4' and the anomeric proton of apiosyl showed correlation with C-2'' of glucosyl. The absolute configuration of C-2 was determined as 2S by the ECD data, which is accordance with the other natural flavanones [14]. Therefore, compound **3** was determined as

(2S)-(-)-7,8-dihydroxyflavanone-4'-O- β -D-apiofuranosyl (1 \rightarrow 2)- β -D-glucopyranoside.

By comparing the spectroscopic data with literature values, the 21 known compounds isolated in this investigation were identified as liquiritigenin (**4**) [15], calycosin (**5**) [16], isoliquiritigenin (**6**) [15], 7,4'-dihydroxyflavone (**7**) [17], 3'-hydroxyliquiritigenin (**8**) [18], resokaempferol (**9**) [19], eriodictyol (**10**) [20], ononin (**11**) [21], liquiritin (**12**) [22], calycosin-7-O- β -D-glucoside (**13**) [23], isoliquiritin (**14**) [22], 5-hydroxyliquiritin (**15**) [24], 8-hydroxyliquiritigenin (**16**) [25], isoliquiritin apioside (**17**) [22], licraside (**18**) [26], demethylvestitol (**19**) [27], (3R)-(-)-isomucronulatol-7-O- β -D-glucoside (**20**) [28], liquiritigenin-7,4'-O- β -D-diglycoside (**21**) [29], 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl)-1-propanone (**22**) [30], 5'-hydroxy-4'-methoxyisoflavone-3'-O- β -D-glucoside (**23**) [31], and liquiritin apioside (**24**) [32].

In order to clarify the sources of these isolates, a UPLC-Q-trap-MS method was established to analyze the isolated flavonoids in BYD and in each composition plant. Finally, compounds **3-9**, **11-19**, **21**, **22**, and **24** were found to be originated from *G. uralensis*, while compounds **1**, **2**, **5**, **9**, **10**, **13**, **20**, and **23** were derived from *A. membranaceus* (Fig. 2, Table 2).

BYD has been clinically used for the prevention and treatment of coronary heart disease [5,6]. There are lots of evidences to prove that the coronary heart disease is associated with the inflammation [33,34]. NO, a significant signaling molecule of inflammation, has been reported to be closely related to the progression of myocardial damage [35,36]. Thus, the NO inhibitory model has been used for screening the cardioprotective or anti-inflammation components and studying their mechanism of action [35-38]. Herein, in order to search for the potential cardioprotective and anti-inflammatory

Table 2
The sources of the isolated compounds from Baoyuan Decoction.

Compound	Formula	[M-H] ⁻	Source
1	C ₂₂ H ₂₈ O ₁₀	463.2	A
2	C ₂₈ H ₃₆ O ₁₄	595.2	A
3	C ₂₆ H ₃₀ O ₁₄	565.1	G
4	C ₁₅ H ₁₂ O ₄	255.1	G
5	C ₁₆ H ₁₂ O ₅	283.1	A/G
6	C ₁₅ H ₁₂ O ₄	255.1	G
7	C ₁₅ H ₁₀ O ₄	253.0	G
8	C ₁₅ H ₁₂ O ₅	271.1	G
9	C ₁₅ H ₁₀ O ₅	269.0	A/G
10	C ₁₅ H ₁₂ O ₆	287.1	A
11	C ₂₂ H ₂₂ O ₉	429.1	G
12	C ₂₁ H ₂₂ O ₉	417.1	G
13	C ₂₇ H ₂₂ O ₁₀	445.1	A/G
14	C ₂₁ H ₂₂ O ₉	417.1	G
15	C ₂₁ H ₂₂ O ₁₀	433.1	G
16	C ₁₅ H ₁₂ O ₅	271.1	G
17	C ₂₆ H ₃₀ O ₁₃	549.2	G
18	C ₂₆ H ₃₀ O ₁₃	549.2	G
19	C ₁₅ H ₁₄ O ₄	257.1	G
20	C ₂₃ H ₂₈ O ₁₀	463.2	A
21	C ₂₇ H ₃₂ O ₁₄	579.2	G
22	C ₁₅ H ₁₄ O ₄	273.1	G
23	C ₂₂ H ₂₂ O ₁₁	461.1	A
24	C ₂₆ H ₃₀ O ₁₃	549.2	G

"A" means that the compound was originated from *A. membranaceus*; "G" means that the compound was originated from *G. uralensis*; "A/G" means that the compound was originated from both *A. membranaceus* and *G. uralensis*.

t3.1 **Table 3**
t3.2 NO inhibitory activity of the isolates.

t3.3	Compound	IC ₅₀ (μM)
t3.4	6	1.4
t3.5	7	37.1
t3.6	9	13.8
t3.7	10	9.3
t3.8	14	20.8
t3.9	Quercetin ^a	16.5

t3.10 ^a Positive control.

384 components from BYD, the flavanoids isolated were evaluated
385 for their inhibitory effects against LPS-induced NO production in
386 RAW264.7 macrophages. As shown in Table 3, compounds **6**, **9**,
387 and **10** showed the significant inhibitory effects with IC₅₀ values
388 of 1.4, 13.8, and 9.3 μM, respectively, comparable to or even
389 better than the positive control of quercetin (IC₅₀ = 16.5 μM).
390 Compounds **7** and **14** showed the moderate inhibitory effects
391 with IC₅₀ values of 37.1 and 20.8 μM, respectively. On the other
392 hand, other isolated flavonoids did not show any inhibitory
393 effects (IC₅₀ > 100 μM). The preliminary structure–activity
394 relationship (SAR) analysis showed that the phenolic hydroxyl
395 is an important active functionality, the more the better, such as
396 **10** ≫ **8**, **16**; **9** > **7**. The compound with chalcone skeleton
397 showed the best inhibitory activity when the phenolic hydroxyl
398 number is equal, such as **6** > **9** ≫ **8**, **19**. Moreover, the
399 glycosidation will lead to the activity decreasing obviously,
400 such as only **14** showed a moderate inhibitory activity, and the
401 other glycosides all lost the activities. The better inhibition effect
402 of NO production presented by compounds **6**, **9**, and **10** in
403 macrophages cells indicates that these several compounds may
404 have potential value in the treatment or prevention of coronary
405 heart disease associated with inflammation [35,36].

Q4 4. Uncited reference

[11]

Acknowledgments

This work was financially supported by the National Natural
Sciences Foundation of China (No. 81222051) and the National
Key Technology R&D Program “New Drug Innovation” of China
(Nos. 2012ZX09301002-002-002 and 2012ZX09304-005).

Appendix A. Supplementary data

Supplementary data to this article can be found online at
<http://dx.doi.org/10.1016/j.fitote.2015.04.011>.

References

- 417 [1] Normile D. The new face of traditional Chinese medicine. *Science* 2003;
418 299:188–90.
419 [2] Li P, Qi LW, Wen XD, Sheng LH. Methods for the elucidation of bioactive
420 components and quality control of traditional Chinese medicines. *Chin J*
421 *Nat Med* 2007;5:1–9.
422 [3] Posters. *Clin Microbiol Infect* 2010;16(Supplement 2):133–634.
423 [4] Xie B, Gong T, Tang M, Mi D, Zhang X, Liu J, et al. An approach based on
424 HPLC-fingerprint and chemometrics to quality consistency evaluation of
425 Liuwei Dihuang Pills produced by different manufacturers. *J Pharm*
426 *Biomed* 2008;48:1261–6.

- [5] Wang JL. The experimental research of BaoYuan jia jian fang decoction 427
treating coronary heart disease and angina pectoris. *J MuDanjiang Med* 428
Coll 2005;26:8–12. 429
[6] Sun C, Han Y, Wu Q. Clinical efficacy of Baoyuan Qingxue particles 430
containing different cinnamic aldehyde content on treatment of coronary 431
heart disease in elderly. *Chin J Gerontol* 2013;33:4692–3. 432
[7] Wang X, Gao G, Hu J. Effect of Baoyuan decoction on cellular immune 433
function after mending surgery for ventricular septal defect of infants and 434
preventive effect on pulmonary infection. *J HaiNan Med Coll* 2012;18: 435
235–7. 436
[8] Chang C, Wang G, Zhang L, Tsai W, Chen R, Wu Y, et al. Cardiovascular 437
protective flavonolignans and flavonoids from *Calamus quiquestinervius*. 438
Phytochemistry 2010;71:271–9. 439
[9] Harnafi H, Amrani S. Flavonoids as potent phytochemicals in cardiovas- 440
cular diseases prevention. *Pharmacogn Rev* 2007;1:193–202. 441
[10] Slade D, Ferreira D, Marais JPJ. Circular dichroism, a powerful tool for the 442
assessment of absolute configuration of flavonoids. *Phytochemistry* 2005; 443
66:2177–215. 444
[11] Giorgio E, Parrinello N, Caccamese S, Rosini C. Non-empirical assignment 445
of the absolute configuration of (–)-naringenin, by coupling the exciton 446
analysis of the circular dichroism spectrum and the *ab initio* calculation of 447
the optical rotatory power. *Org Biomol Chem* 2004;2:3602–7. 448
[12] Çaliş İ, Saracoğlu İ, Başaran AA, Sticher O. Two phenethyl alcohol 449
glycosides from *Scutellaria orientalis* subsp. *pinnatifida*. *Phytochemistry* 450
1993;32:1621–3. 451
[13] Villinski JR, Bergeron C, Cannistra J, Gloer JB, Coleman CM, Ferreira D. 452
et al. Pyrano-isoflavans from *Glycyrrhiza uralensis* with antibacterial 453
activity against *Streptococcus mutans* and *Porphyrromonas gingivalis*. *J Nat* 454
Prod 2014;77:521–6. 455
[14] Tchuendem MHK, Douanla PD, Tabopda TK, Tchinda AT, Tamze V, 456
Nkengfack AE, et al. Two new glycosides from *Duboscia macrocarpa* 457
Bocq. *Phytochem Lett* 2014;10:1–4. 458
[15] Piccinelli AL, Campo Fernandez M, Cuesta-Rubio O, Márquez Hernández I, 459
De Simone F, Rastrelli L. Isoflavonoids isolated from cuban propolis. *J Agric* 460
Food Chem 2005;53:9010–6. 461
[16] Fedoreyev SA, Bulgakov VP, Grishchenko OV, Veselova MV, Krivoschekova 462
OE, Kulesh NI, et al. Isoflavonoid composition of a callus culture of the 463
Relict Tree *Maackia amurensis* Rupr. et Maxim. *J Agric Food Chem* 2008;56: 464
7023–31. 465
[17] Park Y, Moon B, Lee E, Lee Y, Yoon Y, Ahn J, et al. ¹H and ¹³C-NMR data of 466
hydroxyflavone derivatives. *Magn Reson Chem* 2007;45:674–9. 467
[18] Gerardo M. Phenolic derivatives from fruits of *Dipteryx lacunifera* Ducke 468
and evaluation of their antiradical activities. *Helv Chim Acta* 2008;91: 469
2159–67. 470
[19] Kim H, Moon B, Ahn J, Lim Y. Complete NMR signal assignments of flavonol 471
derivatives. *Magn Reson Chem* 2006;44:188–90. 472
[20] Huang D, Chung C, Kuo Y, Lin Y, Chiang W. Identification of compounds in 473
adlay (*Coix lachryma-jobi* L. var. *ma-yuen* Stapf) seed hull extracts that 474
inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macro- 475
phages. *J Agric Food Chem* 2009;57:10651–7. 476
[21] Ryu YB, Kim JH, Park S, Chang JS, Rho M, Bae K, et al. Inhibition of 477
neuraminidase activity by polyphenol compounds isolated from the roots 478
of *Glycyrrhiza uralensis*. *Bioorg Med Chem Lett* 2010;20:971–4. 479
[22] Fu B, Li H, Wang X, Lee FSC, Cui S. Isolation and identification of flavonoids 480
in licorice and a study of their inhibitory effects on tyrosinase. *J Agric Food* 481
Chem 2005;53:7408–14. 482
[23] Du X, Bai Y, Liang H, Wang Z, Zhao Y, Zhang Q, et al. Solvent effect in ¹H 483
NMR spectra of 3'-hydroxy-4'-methoxy isoflavonoids from *Astragalus* 484
membranaceus var. *mongholicus*. *Magn Reson Chem* 2006;44:708–12. 485
[24] Sachiko EKN. Preparation and taste of certain glycosides of flavanones and 486
of dihydrochalcones. *Biosci Biotechnol Biochem* 1994;58:1479–85. 487
[25] Edenharder R, Keller G, Platt KL, Unger KK. Isolation and characterization 488
of structurally novel antimutagenic flavonoids from Spinach (*Spinacia* 489
oleracea). *J Agric Food Chem* 2001;49:2767–73. 490
[26] Isao K, Saponin, Sapogenol. On the constituents of the roots of *Glycyrrhiza* 491
uralensis Fischer from Xinjiang, China. chemical structures of licorice- 492
saponin L3 and isoliquiritin apioside. *Chem Pharm Bull* 1993;41:1567–72. 493
[27] Naoki A, Hiroji S, Sadao S. Antifungal stress compounds from Adzuki Bean, 494
Vigna angularis, treated with cephalosporium gregatum. *Agric Biol Chem* 495
1987;2:349–53. 496
[28] Li W, Sun YN, Yan XT, Yang SY, Kim S, Lee YM, et al. Flavonoids from 497
Astragalus membranaceus and their inhibitory effects on LPS-stimulated 498
pro-inflammatory cytokine production in bone marrow-derived dendritic 499
cells. *Arch Pharm Res* 2014;37:186–92. 500
[29] Derese S, Barasa L, Akala HM, Yusuf AO, Kamau E, Heydenreich M, et al. 4'- 501
Prenyloxyderrone from the stem bark of *Milletia oblata* ssp. *teitensis* and 502
the antiparasitodal activities of isoflavones from some *Milletia* species. 503
Phytochem Lett 2014;8:69–72. 504
[30] Rafi MM, Vastano BC, Zhu N, Ho C, Ghai G, Rosen RT, et al. Novel 505
polyphenol molecule isolated from Licorice root (*Glycyrrhiza glabra*) 506

- 507 induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in
508 tumor cell lines. *J Agric Food Chem* 2002;50:677–84.
- 509 [31] Shen Y, Feng Z, Jiang J, Yang Y, Zhang P. Dibenzoyl and isoflavonoid
510 glycosides from *Sophora flavescens*: inhibition of the cytotoxic effect of
511 D-galactosamine on human hepatocyte HL-7702. *J Nat Prod* 2013;76:
512 2337–45.
- 513 [32] Asano T, Ishihara K, Morota T, Takeda S, Aburada M. Permeability of the
514 flavonoids liquiritigenin and its glycosides in licorice roots and
515 daidigenin, a hydrogenated metabolite of liquiritigenin, using human
516 intestinal cell line Caco-2. *J Ethnopharmacol* 2003;89:285–9.
- 517 [33] Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory
518 disorders and risk of type 2 diabetes mellitus, coronary heart disease, and
519 stroke: a population-based cohort study. *Circulation* 2014;130:837–44.
- 520 [34] Gao S, Wang L, Liu W, Wu Y, Yuan Z. The synergistic effect of homocysteine
521 and lipopolysaccharide on the differentiation and conversion of RAW
522 264.7 macrophages. *J Inflamm* 2014;11:13–9.
- 523 [35] Li YC, Luo Q, Ge LS, Chen YH, Zhou ND, Zhang T, et al. Ivabradine inhibits
524 the production of proinflammatory cytokines and inducible nitric oxide
525 synthase in acute coxsackievirus B3-induced myocarditis. *Biochem*
526 *Biophys Res Commun* 2013;431:450–5.
- 527 [36] Shigeru I, Michiaki H, Toshio N, Shinji A, Takashi S, Hiroshi I, et al. Nitric
528 oxide contributes to the progression of myocardial damage in experi-
529 mental autoimmune myocarditis in rats. *Circulation* 1997;95:489–96.
- 530 [37] Lv HN, Wang S, Zeng KW, Li J, Guo XY, Ferreira D, et al. Anti-inflammatory
531 coumarin and benzocoumarin derivatives from *Murraya alata*. *J Nat Prod*
532 2015;78:279–85.
- 533 [38] Jiang Y, Zeng KW, David B, Massiot G. Constituents of *Vigna angularis* and
534 their in vitro anti-inflammatory activity. *Phytochemistry* 2014;107:111–8.

UNCORRECTED PROOF